Haleon updates share count and voting rights

Haleon plc (LSE/NYSE: HLN), a leading global consumer health company with a market capitalization of $45.7 billion, announced today that as of March 31, 2025, the total number of issued shares stands at 9,038,156,791 ordinary shares, each with a nominal value of £0.01. The company, which is known for brands such as Advil, Sensodyne, and Centrum and generates annual revenues of $14 billion, has specified that 4,080,205 of these shares are held in treasury.

Accordingly, the number of ordinary shares carrying voting rights totals 9,034,076,586. Shareholders and other parties with notification obligations are advised to use this figure as the denominator for calculations to determine if they must disclose changes in their stake in the company under the Financial Conduct Authority’s (FCA) Disclosure Guidance and Transparency Rules. The stock currently trades near its 52-week high with notably low volatility, maintaining a beta of 0.23.

The announcement, made through a Form 6-K filing with the Securities and Exchange Commission, serves to keep shareholders informed about their voting rights within the company. Haleon emphasized the importance of this information for those who are required to notify their interests or any changes to their interest in the company.

Haleon, which operates in five major categories including Oral Health, Pain Relief, and Vitamins, Minerals and Supplements (VMS), underlines its commitment to delivering everyday health benefits to consumers through trusted science and innovation.

This latest corporate update is based on a press release statement and reflects the company’s status as of the end of the previous month. For further details, interested parties may contact Haleon’s company secretary at the provided email address within the filing.

Investors and market watchers often scrutinize such updates for insights into a company’s capital structure and potential changes in shareholder influence. Haleon’s disclosure ensures transparency and compliance with regulatory requirements.

In other recent news, Haleon plc has launched a £330 million share buyback program, intending to repurchase its ordinary shares to enhance shareholder value. This initiative follows the completion of an off-market purchase of shares from Pfizer Inc. (NYSE:PFE), which resulted in the cancellation of 44,155,844 shares. The buyback is part of a broader strategy to manage the company’s capital effectively and is expected to positively impact earnings per share. Additionally, Haleon has granted conditional share awards to its top executives, aligning their compensation with company performance and long-term value creation. CEO Brian McNamara received a significant portion of these awards, which are contingent on performance conditions assessed by December 31, 2027.

Furthermore, Haleon has published its Annual Report and Form 20-F for the year ending December 31, 2024, providing a detailed overview of its financial performance. The report is publicly accessible and highlights the company’s diverse product portfolio and commitment to innovation. In related developments, Pfizer has exited its shareholder position in Haleon, concluding a gradual divestment process that began in 2022. This exit is part of a larger £500 million repurchase plan disclosed earlier this year. Haleon’s leadership remains focused on leveraging growth opportunities and enhancing shareholder returns, as evidenced by these strategic financial maneuvers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.